COHEN & STEERS INC (CNS) Fundamental Analysis & Valuation

NYSE:CNS • US19247A1007

64.96 USD
-1.25 (-1.89%)
At close: Mar 6, 2026
64.96 USD
0 (0%)
After Hours: 3/6/2026, 8:09:20 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CNS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to CNS. CNS was compared to 238 industry peers in the Capital Markets industry. While CNS has a great profitability rating, there are some minor concerns on its financial health. CNS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. CNS Profitability Analysis

1.1 Basic Checks

  • In the past year CNS was profitable.
  • In the past year CNS has reported a negative cash flow from operations.
  • In the past 5 years CNS has always been profitable.
  • Of the past 5 years CNS 4 years had a positive operating cash flow.
CNS Yearly Net Income VS EBIT VS OCF VS FCFCNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

1.2 Ratios

  • With an excellent Return On Assets value of 20.48%, CNS belongs to the best of the industry, outperforming 97.06% of the companies in the same industry.
  • With an excellent Return On Equity value of 29.83%, CNS belongs to the best of the industry, outperforming 94.54% of the companies in the same industry.
  • CNS has a better Return On Invested Capital (24.42%) than 97.90% of its industry peers.
Industry RankSector Rank
ROA 20.48%
ROE 29.83%
ROIC 24.42%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNS Yearly ROA, ROE, ROICCNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • CNS's Profit Margin of 29.73% is fine compared to the rest of the industry. CNS outperforms 71.43% of its industry peers.
  • In the last couple of years the Profit Margin of CNS has grown nicely.
  • The Operating Margin of CNS (33.83%) is better than 64.29% of its industry peers.
  • CNS's Operating Margin has declined in the last couple of years.
  • CNS's Gross Margin of 88.60% is amongst the best of the industry. CNS outperforms 92.86% of its industry peers.
  • In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
Industry RankSector Rank
OM 33.83%
PM (TTM) 29.73%
GM 88.6%
OM growth 3Y-4.66%
OM growth 5Y-2.01%
PM growth 3Y-3.48%
PM growth 5Y8.65%
GM growth 3Y0.67%
GM growth 5Y0.08%
CNS Yearly Profit, Operating, Gross MarginsCNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CNS Health Analysis

2.1 Basic Checks

  • CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CNS Yearly Shares OutstandingCNS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CNS Yearly Total Debt VS Total AssetsCNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 9.27 indicates that CNS is not in any danger for bankruptcy at the moment.
  • CNS has a Altman-Z score of 9.27. This is amongst the best in the industry. CNS outperforms 92.44% of its industry peers.
  • CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.27
ROIC/WACCN/A
WACCN/A
CNS Yearly LT Debt VS Equity VS FCFCNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.3 Liquidity

  • A Current Ratio of 0.79 indicates that CNS may have some problems paying its short term obligations.
  • The Current ratio of CNS (0.79) is worse than 62.60% of its industry peers.
  • CNS has a Quick Ratio of 0.79. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CNS has a Quick ratio of 0.79. This is in the lower half of the industry: CNS underperforms 62.18% of its industry peers.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.79
CNS Yearly Current Assets VS Current LiabilitesCNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CNS Growth Analysis

3.1 Past

  • CNS shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.80%.
  • CNS shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.74% yearly.
  • Looking at the last year, CNS shows a small growth in Revenue. The Revenue has grown by 7.04% in the last year.
  • Measured over the past years, CNS shows a small growth in Revenue. The Revenue has been growing by 5.73% on average per year.
EPS 1Y (TTM)5.8%
EPS 3Y-5.81%
EPS 5Y3.74%
EPS Q2Q%3.85%
Revenue 1Y (TTM)7.04%
Revenue growth 3Y-0.12%
Revenue growth 5Y5.73%
Sales Q2Q%17.21%

3.2 Future

  • Based on estimates for the next years, CNS will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.66% on average per year.
  • Based on estimates for the next years, CNS will show a small growth in Revenue. The Revenue will grow by 6.70% on average per year.
EPS Next Y8.82%
EPS Next 2Y10.9%
EPS Next 3Y8.22%
EPS Next 5Y8.66%
Revenue Next Year7.29%
Revenue Next 2Y9.14%
Revenue Next 3Y7.24%
Revenue Next 5Y6.7%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CNS Yearly Revenue VS EstimatesCNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
CNS Yearly EPS VS EstimatesCNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

2

4. CNS Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 20.95, the valuation of CNS can be described as rather expensive.
  • Based on the Price/Earnings ratio, CNS is valued a bit more expensive than 65.97% of the companies in the same industry.
  • CNS is valuated rather cheaply when we compare the Price/Earnings ratio to 26.29, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 19.26, the valuation of CNS can be described as rather expensive.
  • CNS's Price/Forward Earnings is on the same level as the industry average.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.57, CNS is valued a bit cheaper.
Industry RankSector Rank
PE 20.95
Fwd PE 19.26
CNS Price Earnings VS Forward Price EarningsCNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than 75.63% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.54
CNS Per share dataCNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CNS does not grow enough to justify the current Price/Earnings ratio.
  • CNS has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.38
PEG (5Y)5.6
EPS Next 2Y10.9%
EPS Next 3Y8.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. CNS Dividend Analysis

5.1 Amount

  • CNS has a Yearly Dividend Yield of 3.69%. Purely for dividend investing, there may be better candidates out there.
  • CNS's Dividend Yield is comparable with the industry average which is at 6.33.
  • CNS's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 3.69%

5.2 History

  • The dividend of CNS decreases each year by -7.12%.
  • CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
  • The dividend of CNS decreased in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
CNS Yearly Dividends per shareCNS Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3

5.3 Sustainability

  • CNS pays out 76.25% of its income as dividend. This is not a sustainable payout ratio.
DP76.25%
EPS Next 2Y10.9%
EPS Next 3Y8.22%
CNS Yearly Income VS Free CF VS DividendCNS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
CNS Dividend Payout.CNS Dividend Payout, showing the Payout Ratio.CNS Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

CNS Fundamentals: All Metrics, Ratios and Statistics

COHEN & STEERS INC

NYSE:CNS (3/6/2026, 8:09:20 PM)

After market: 64.96 0 (0%)

64.96

-1.25 (-1.89%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)01-22
Earnings (Next)04-14
Inst Owners58.73%
Inst Owner Change-1.96%
Ins Owners22.81%
Ins Owner Change5.46%
Market Cap3.31B
Revenue(TTM)553.87M
Net Income(TTM)164.16M
Analysts48
Price Target71.91 (10.7%)
Short Float %7.01%
Short Ratio5.95
Dividend
Industry RankSector Rank
Dividend Yield 3.69%
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.25%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.39%
Min EPS beat(2)-4.27%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-0.86%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)3
Avg EPS beat(8)-0.49%
EPS beat(12)5
Avg EPS beat(12)0.41%
EPS beat(16)9
Avg EPS beat(16)1.94%
Revenue beat(2)1
Avg Revenue beat(2)-0.16%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)-2.44%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-1.39%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.44%
PT rev (3m)-11.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.82%
EPS NY rev (1m)0.3%
EPS NY rev (3m)-2.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.69%
Revenue NY rev (1m)-0.97%
Revenue NY rev (3m)-3.17%
Valuation
Industry RankSector Rank
PE 20.95
Fwd PE 19.26
P/S 6
P/FCF N/A
P/OCF N/A
P/B 6.02
P/tB 6.25
EV/EBITDA 16.54
EPS(TTM)3.1
EY4.77%
EPS(NY)3.37
Fwd EY5.19%
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS10.82
BVpS10.79
TBVpS10.39
PEG (NY)2.38
PEG (5Y)5.6
Graham Number27.43
Profitability
Industry RankSector Rank
ROA 20.48%
ROE 29.83%
ROCE 31.59%
ROIC 24.42%
ROICexc 29.28%
ROICexgc 32.82%
OM 33.83%
PM (TTM) 29.73%
GM 88.6%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-4.66%
OM growth 5Y-2.01%
PM growth 3Y-3.48%
PM growth 5Y8.65%
GM growth 3Y0.67%
GM growth 5Y0.08%
F-Score5
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 63.99%
Cap/Sales 1.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.79
Altman-Z 9.27
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.8%
EPS 3Y-5.81%
EPS 5Y3.74%
EPS Q2Q%3.85%
EPS Next Y8.82%
EPS Next 2Y10.9%
EPS Next 3Y8.22%
EPS Next 5Y8.66%
Revenue 1Y (TTM)7.04%
Revenue growth 3Y-0.12%
Revenue growth 5Y5.73%
Sales Q2Q%17.21%
Revenue Next Year7.29%
Revenue Next 2Y9.14%
Revenue Next 3Y7.24%
Revenue Next 5Y6.7%
EBIT growth 1Y15.71%
EBIT growth 3Y-4.78%
EBIT growth 5Y3.6%
EBIT Next Year-2.4%
EBIT Next 3Y14.61%
EBIT Next 5Y11.96%
FCF growth 1Y-194.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-171.97%
OCF growth 3YN/A
OCF growth 5YN/A

COHEN & STEERS INC / CNS FAQ

What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CNS.


What is the valuation status for CNS stock?

ChartMill assigns a valuation rating of 2 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.


Can you provide the profitability details for COHEN & STEERS INC?

COHEN & STEERS INC (CNS) has a profitability rating of 7 / 10.


Can you provide the financial health for CNS stock?

The financial health rating of COHEN & STEERS INC (CNS) is 5 / 10.


What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?

The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 8.82% in the next year.